Selecta Biosciences (NASDAQ:SELB)‘s stock had its “buy” rating reiterated by equities research analysts at Canaccord Genuity in a research note issued to investors on Wednesday. They presently have a $40.00 target price on the stock. Canaccord Genuity’s target price suggests a potential upside of 196.30% from the stock’s previous close.
The analysts wrote, “We expect Selecta to present positive 5-dose Phase 2 combination data for SEL-212 in severe gout during 3Q18, and see significant upside for the stock. Selecta is likely to present data from multiple dosing cohorts, with up to n=20 patients from each cohort. We suspect focus will be on the 0.15 mg/kg SVP-rapamycin + 0.20 pegsiticase dose, but await upcoming data. We see little reason that SEL-212 will not reproduce data at 5 months similar to that seen at 3 months, where ~80% Serum Uric Acid control was shown.””
A number of other research firms have also commented on SELB. ValuEngine raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, July 5th. Zacks Investment Research raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, May 15th. Mizuho reaffirmed a “buy” rating and set a $30.00 price target on shares of Selecta Biosciences in a research report on Wednesday, April 11th. Janney Montgomery Scott began coverage on shares of Selecta Biosciences in a report on Wednesday, June 27th. They issued a “buy” rating and a $33.00 target price on the stock. Finally, BidaskClub raised shares of Selecta Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 15th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $28.25.
Selecta Biosciences traded down $0.09, reaching $13.50, during mid-day trading on Wednesday, MarketBeat Ratings reports. 191,804 shares of the company’s stock were exchanged, compared to its average volume of 264,850. Selecta Biosciences has a one year low of $7.95 and a one year high of $24.02. The firm has a market cap of $298.37 million, a price-to-earnings ratio of -4.22 and a beta of -3.64. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.20 and a current ratio of 7.20.
Selecta Biosciences (NASDAQ:SELB) last released its quarterly earnings results on Wednesday, May 9th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.11). Selecta Biosciences had a negative return on equity of 111.69% and a negative net margin of 31,556.04%. sell-side analysts anticipate that Selecta Biosciences will post -2.88 EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in the business. Polaris Venture Management Co. V L.L.C. bought a new position in Selecta Biosciences in the 2nd quarter valued at about $26,919,000. Perceptive Advisors LLC boosted its stake in shares of Selecta Biosciences by 45.8% in the 3rd quarter. Perceptive Advisors LLC now owns 1,162,325 shares of the company’s stock valued at $21,212,000 after purchasing an additional 365,000 shares in the last quarter. Vivo Capital LLC acquired a new stake in shares of Selecta Biosciences in the 2nd quarter valued at approximately $22,227,000. Deerfield Management Co. acquired a new stake in shares of Selecta Biosciences in the 4th quarter valued at approximately $14,632,000. Finally, BlackRock Inc. boosted its stake in shares of Selecta Biosciences by 1.6% in the 1st quarter. BlackRock Inc. now owns 629,978 shares of the company’s stock valued at $6,420,000 after purchasing an additional 9,749 shares in the last quarter. 46.03% of the stock is currently owned by hedge funds and other institutional investors.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.